Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518631-11-00

Acronym

Sign

Enrollment

Registered

2024-12-11

Start date

2023-04-25

Completion date

Unknown

Last updated

2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal cancer

Brief summary

The primary endpoint of this study is the rate of best responses per any timepoint during study period after administration of at least one cycle of immunochemotherapy defined as CR and PR according to RECIST 1.1 criteria

Detailed description

• Progression-free survival • Overall survival • Toxicity • Quality of life analyses • Depression scale analyses

Interventions

DRUGSertralin ratiopharm 50 mg Filmtabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study is the rate of best responses per any timepoint during study period after administration of at least one cycle of immunochemotherapy defined as CR and PR according to RECIST 1.1 criteria	—

Secondary

Measure	Time frame
• Progression-free survival • Overall survival • Toxicity • Quality of life analyses • Depression scale analyses	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026